Ian Roberts

Ian Roberts

Auto-generated profile, based on publicly available information

Ian Roberts

Healx Ltd., Cambridge, UK

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
IRIan Roberts
Ian Roberts
GNGrace Ng
Grace Ng
NFNicola Foster
Nicola Foster
MSMargaret Stanley
Margaret Stanley
MHMichael T Herdman
Michael T Herdman
NCNicholas Coleman
Nicholas Coleman
Human papilloma virus (HPV) load and physical status are considered useful parameters for clinical evaluation of cervical squamous cell neoplasia. However, the errors implicit in HPV gene quantification by PCR are not well documented. We have undertaken the first rigorous evaluation of the errors that can be expected when using SYBR green qPCR for quantification of HPV type 16 gene copy numbers. We assessed a modified method, in which external calibration curves were generated from a single construct containing HPV16 E2, HPV16 E6 and the host gene hydroxymethylbilane synthase in a 1:1:1 ratio. When testing dilutions of mixed HPV/host DNA in replicate runs, we observed errors in quantifying E2 and E6 amplicons of 5–40%, with greatest error at the lowest DNA template concentration (3 ng/μl). Errors in determining viral copy numbers per diploid genome were 13–53%. Nevertheless, in cervical keratinocyte cell lines we observed reasonable agreement between viral loads determined by qPCR and Southern blotting. The mean E2/E6 ratio in episome-only cells was 1.04, but with a range of 0.76–1.32. In three integrant-only lines the mean E2/E6 ratios were 0.20, 0.72 and 2.61 (values confirmed by gene-specific Southern blotting). When E2/E6 ratios in fourteen HPV16-positive cervical carcinomas were analysed, conclusions regarding viral physical state could only be made in three cases, where the E2/E6 ratio was ≤ 0.06. Run-to-run variation in SYBR green qPCR produces unavoidable inaccuracies that should be allowed for when quantifying HPV gene copy number. While E6 copy numbers can be considered to provide a useable indication of viral loads, the E2/E6 ratio is of limited value. Previous studies may have overestimated the frequency of mixed episomal/integrant HPV infections.

8 July 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSaatviga Sudhahar
Saatviga Sudhahar
BOBugra Ozer
Bugra Ozer
JCJiakang Chang
Jiakang Chang
WCWayne Chadwick
Wayne Chadwick
DODaniel O’donovan
Daniel O’donovan
IRIan Roberts
Ian Roberts
Explaining predictions for drug repositioning with biological knowledge graphs is a challenging problem. Graph completion methods using symbolic reasoning predict drug treatments and associated rules to generate evidence representing the therapeutic basis of the drug. Yet the vast amounts of generated paths that are biologically irrelevant or not mechanistically meaningful within the context of disease biology can limit utility. We use a reinforcement learning based knowledge graph completion model combined with an automatic filtering approach that produces the most relevant rules and biological paths explaining the predicted drug’s therapeutic connection to the disease. In this work we validate the approach against preclinical experimental data for Fragile X syndrome demonstrating strong correlation between automatically extracted paths and experimentally derived transcriptional changes of selected genes and pathways of drug predictions Sulindac and Ibudilast. Additionally, we show it reduces the number of generated paths in two case studies, 85% for Cystic fibrosis and 95% for Parkinson’s disease.

12 July 2005 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
RHRuth Ms Hansen
Ruth Ms Hansen
AGAnne Goriely
Anne Goriely
SWSteven A Wall
Steven A Wall
IRIan Sd Roberts
Ian Sd Roberts
AWAndrew O. M. Wilkie
Andrew O. M. Wilkie

1 July 2001 in Cytogenetic and Genome Research
Verified
Journal Article
Closed access
PDF file
IRI. Roberts
I. Roberts
AGAdam Lee Gordon
Adam Lee Gordon
RWR. Wang
R. Wang
KPK. Pritchard-Jones
K. Pritchard-Jones
Janet ShipleyJanet Shipley
Janet Shipley
NCN. Coleman
N. Coleman
Rhabdomyosarcoma in children is a “small round blue cell tumour” that displays skeletal muscle differentiation. Two main histological variants are recognised, alveolar (ARMS) and embryonal (ERMS) rhabdomyosarcoma. Whereas consistent chromosome translocations characteristic of ARMS have been reported, no such cytogenetic abnormality has yet been described in ERMS. We have used multiple colour chromosome painting to obtain composite karyotypes for five ERMS cell lines and one PAX-FOXO1A fusion gene negative ARMS. The cell lines were assessed by spectral karyotyping (SKY), tailored multi-fluorophore fluorescence in situ hybridisation (M-FISH) using series of seven colour paint sets generated to examine specific abnormalities, and comparative genomic hybridisation (CGH). This approach enabled us to obtain karyotypes of the cell lines in greater detail than previously possible. Several recurring cytogenetic abnormalities were demonstrated, including translocations involving chromosomes 1 and 15 and chromosomes 2 and 15, in 4/6 and 2/6 cell lines respectively. All six cell lines demonstrated abnormalities of chromosome 15. Translocations between chromosomes 1 and 15 have previously been recorded in two primary cases of ERMS by conventional cytogenetics. Analysis of the translocation breakpoints may suggest mechanisms of ERMS tumourigenesis and may enable the development of novel approaches to the clinical management of this tumour.

6 June 2019 in Rheumatology
Verified
Journal Article
Closed access
AAAzeem Ahmed
Azeem Ahmed
NANadia Ahmad
Nadia Ahmad
VDVinod Dibbur
Vinod Dibbur
EPElizabeth Price
Elizabeth Price
IRIan S. D. Roberts
Ian S. D. Roberts

23 December 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
KRKatarzyna Radke
Katarzyna Radke
KAKristina Aaltonen
Kristina Aaltonen
EMErick A Muciño-Olmos
Erick A Muciño-Olmos
JEJavanshir Esfandyari
Javanshir Esfandyari
AAAleksandra Adamska
Aleksandra Adamska
DBDaniel Bexell
Daniel Bexell
Relapse and treatment resistance are common in children with high-risk neuroblastoma, and novel therapies are needed. Conventional drug discovery is slow, expensive, often fails in practice, and consequently falls short in addressing pediatric and rare conditions. In such instances, drug repurposing is a promising strategy. Here, we used two independent in silico prediction tools including machine learning to identify approved drugs for repurposing against neuroblastoma. The combination of statins and phenothiazines showed strong synergistic effects in human neuroblastoma organoids, decreased tumor growth, and prolonged survival in MYCN -amplified neuroblastoma patient-derived xenografts. The drug combination altered cholesterol metabolism through two different mechanisms and induced a phenotypic change toward an adrenergic state in vitro, which was associated with enhanced chemosensitivity. Integration of the drug combination into standard-of-care chemotherapy regressed tumors and prolonged survival in chemoresistant patient-derived xenografts. Thus, a combination of safe and approved medications added to standard-of-care chemotherapy outperforms chemotherapy alone in chemoresistant neuroblastoma.